What is RPG Life Sciences Ltd (RPGLIFE) share price return in the past 10 years?

RPG Life Sciences Ltd share price has appreciated 24.6% annually (CAGR) over the past ten years.

What is the share price of RPG Life Sciences Ltd (RPGLIFE)?

Company share prices are keep on changing according to the market conditions. The current trading price of RPG Life Sciences Ltd (RPGLIFE) on 03-Jul-2026 16:59:59 at 16:59 is 2416.65.

What is the P/E ratio of RPG Life Sciences?

The latest standalone P/E ratio of RPG Life Sciences as of 03-Jul-2026 is 34.70.

What is the P/B ratio of RPG Life Sciences Ltd (RPGLIFE)?

The latest standalone P/B ratio of RPG Life Sciences Ltd (RPGLIFE) as of 03-Jul-2026 is 6.60.

What is the 52-week high and low of RPG Life Sciences Ltd (RPGLIFE)?

The 52-week high of RPG Life Sciences Ltd (RPGLIFE) is Rs. 2715.90 and the 52-week low is Rs. 1731.25.

RPG Life Sciences Ltd (RPGLIFE) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: RPG Life Sciences Ltd (RPGLIFE)
Brand: RPG Life Sciences

Key Metrics

Valuation Multiples

Market Cap

₹3,997 Cr.

Current Price

₹2,416.7

52-Week Low / High

₹1,731 / 2,716

TTM EPS

₹69.6

TTM Sales

₹708 Cr.

Book Value per Share

₹366

P/E Ratio

34.70

Higher than its 5-year historical median

Industry PE

49.8

Price to Book (P/B)

6.60

Higher than its 5-year historical median

Price to Sales (P/S)

5.65

Higher than its 5-year historical median

EV/EBITDA

22.24

Higher than its 5-year historical median

Dividend Yield

0.99%

Profitability Efficiency

Return on Equity (ROE)

20.28%

Outperforms industry median

Return on Capital Employed (ROCE)

26.99%

Outperforms industry median

Return on Assets (ROA)

15.89%

Operating Profit Margin

20.9%

Net Profit Margin

16.28%

Gross Profit Margin

22.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

8.28%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-6.91%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-37.15%

Asset Quality

Promoter Holding

72.95%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹592 Cr.

Equity

₹13.2 Cr.

Face Value

₹8

All Time Low / High

₹17.10 / 2976.70

RPG Life Sciences stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is RPG Life Sciences Ltd a good quality company?

RPG Life Sciences Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does RPG Life Sciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of RPG Life Sciences Ltd vs industry peers?

RPG Life Sciences Ltd revenue CAGR is 11.71%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of RPG Life Sciences Ltd?

Promoters hold 72.95% of the RPG Life Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of RPG Life Sciences Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 24.7% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	10.5%	12.5%	9.8%	20.4%	27.3%	31.5%	32.9%	35%	51.8%	27%	-
Value Creation Index ⓘ	-0.3	-0.1	-0.3	0.5	1.0	1.3	1.4	1.5	2.7	0.9	-
Growth Parameters ⓘ
Sales ⓘ	294	344	330	376	389	440	513	582	653	708	708
Sales YoY Gr.	-	17.1%	-4%	13.8%	3.6%	13.1%	16.5%	13.5%	12.3%	8.3%	-
Adj EPS ⓘ	7.4	8	6.3	19.6	24	30.8	41	53	75.3	64.1	69.6
YoY Gr.	-	9%	-21.7%	212.4%	22.2%	28.5%	33%	29.3%	42%	-14.9%	-
BVPS (₹) ⓘ	88.9	93.6	97.1	106.8	130.9	154.7	186	226.7	320.8	366.1	366
Adj Net Profit ⓘ	12.2	13.3	10.4	32.5	39.7	51	67.8	87.7	124	106	115
Cash Flow from Ops. ⓘ	7.3	14.7	45.8	50.2	58.3	64.8	90.8	94.4	77.9	56.5	-
Debt/CF from Ops. ⓘ	6.1	3.7	0.8	0.2	0	0	0	0	0	0.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.3%	12.7%	11.3%	8.3%
Adj EPS ⓘ	27.2%	21.7%	16.1%	-14.9%
BVPSⓘ	17%	22.8%	25.3%	14.1%
Share Price	24.6%	40.4%	36.7%	-4.3%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	8.7	8.8	6.6	19.3	20.2	21.6	24.1	25.7	27.5	18.7	19
Op. Profit Mgn % ⓘ	9.8	10.8	10.5	16	18.2	19.8	20.3	22.2	24.3	20.9	20.8
Net Profit Mgn % ⓘ	4.1	3.9	3.2	8.6	10.2	11.6	13.2	15.1	19.1	15	16.3
Debt to Equity ⓘ	0.3	0.4	0.2	0.1	0	0	0	0	0	0	0
Working Cap Days ⓘ	123	113	122	105	118	105	97	96	98	120	127
Cash Conv. Cycle ⓘ	49	44	44	40	44	40	30	23	26	41	89

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	294	344	330	376	389	440	513	582	653	708
Operating Expenses ⓘ +	265	307	296	316	318	353	409	453	494	560
Manufacturing Costs	30	32	29	33	40	51	50	58	64	68
Material Costs	96	107	104	120	121	128	157	168	197	233
Employee Cost	76	90	90	91	95	100	117	132	126	141
Other Costs ⓘ	64	78	73	72	62	75	85	95	108	117
Operating Profit ⓘ	29	37	34	60	71	87	104	129	159	148
Operating Profit Margin (%)	9.8%	10.8%	10.4%	15.9%	18.2%	19.8%	20.2%	22.2%	24.3%	20.9%
Other Income ⓘ +	1	2	1	1	1	3	5	7	14	26
Exceptional Items ⓘ	0	0	0	-5	0	0	0	0	83	4
Interest ⓘ	4	5	5	3	2	1	1	1	2	2
Depreciation ⓘ	11	14	15	16	16	16	16	17	21	21
Profit Before Tax ⓘ	15	20	15	36	54	73	92	118	233	154
Tax ⓘ	2	7	4	7	14	22	24	30	50	39
Profit After Tax	12	13	11	29	40	51	68	88	183	115
PAT Margin (%)	4.1%	3.9%	3.3%	7.7%	10.3%	11.7%	13.2%	15.1%	28.0%	16.3%
Adjusted EPS (₹)	7.3	8.1	6.5	17.5	24.2	31.1	40.9	53.0	110.8	69.6
Dividend Payout Ratio (%)	38.30%	29.50%	36.70%	22.80%	29.80%	30.80%	29.30%	30.20%	21.70%	34.50%

Valuation of RPG Life Sciences - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	147	155	161	177	216	256	308	375	531	605
Share Capital ⓘ	13	13	13	13	13	13	13	13	13	13
Reserves ⓘ	134	142	147	163	203	243	294	362	517	592
Debt +	40	48	36	7	1	1	0	0	0	13
Long Term Debt	16	10	7	2	1	0	0	0	0	13
Short Term Debt	24	38	29	5	1	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	29	52	25	44	47	46	65	71	79	97
Others Liabilities ⓘ	21	29	27	40	38	43	47	66	47	77
Total Liabilities ⓘ	236	284	248	268	303	345	419	512	657	793
Fixed Assets
Net Fixed Assets ⓘ +	137	131	128	123	113	104	124	114	172	197
Gross Block	142	151	163	174	180	186	220	222	276	321
Accumulated Depreciation	6	20	35	51	67	83	96	108	104	125
CWIP ⓘ	2	9	17	10	12	31	25	96	16	23
Investments ⓘ	0	0	0	0	0	0	58	91	127	120
Inventories	46	54	41	47	58	83	95	101	93	124
Trade Receivables	39	68	39	63	57	33	37	49	87	117
Cash Equivalents ⓘ	2	1	1	1	41	70	57	36	140	157
Others Assets ⓘ	11	22	22	24	22	24	22	25	23	56
Total Assets ⓘ	236	284	248	268	303	345	419	512	657	793

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	7	15	46	50	58	65	91	94	78	57
PBT ⓘ	23	20	15	36	54	73	92	118	233	154
Adjustment ⓘ	7	17	20	23	17	14	13	13	-76	-17
Changes in Working Capital ⓘ	-19	-19	14	-2	-4	-3	11	-7	-26	-43
Tax Paid ⓘ	-4	-4	-4	-6	-8	-19	-25	-29	-53	-37
Cash Flow From Investing Activity ⓘ +	-30	-16	-19	-11	-8	-35	-106	-79	-42	51
Capex	-55	-15	-20	-11	-8	-24	-33	-69	73	-65
Net Investments	-0	-0	0	0	0	-12	-57	-27	-29	48
Others ⓘ	25	0	0	0	1	1	-16	17	-86	68
Cash Flow From Financing Activity ⓘ +	23	0	-27	-39	-10	-14	-17	-20	-27	-21
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	20	-4	-9	-0	-4	-0	-0	-0	0	20
Interest Paid ⓘ	-3	-4	-4	-2	-1	-1	-0	-0	-1	-1
Dividend Paid ⓘ	0	-6	-5	-13	0	-12	-16	-20	-26	-40
Others ⓘ	6	14	-9	-25	-5	-1	-1	0	0	0
Net Cash Flow ⓘ	1	-1	0	0	40	17	-32	-5	9	87

Financial Ratio

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	8.62	8.91	6.86	17.21	20.36	21.8	24.01	25.69	40.48	20.28
ROCE (%)	10.45	12.52	9.81	20.35	27.27	31.46	32.92	34.96	51.79	26.99
Asset Turnover Ratio	1.34	1.48	1.39	1.59	1.47	1.48	1.45	1.34	1.2	1.04
PAT to CFO Conversion(x)	0.58	1.15	4.18	1.72	1.45	1.27	1.34	1.07	0.43	0.5
Working Capital Days
Receivable Days	45.40	50.90	53	45.40	52.50	34.40	23.20	25.30	35.40	49.10
Inventory Days	50.40	47.10	46.90	38.90	45.60	53.80	58.60	57.40	50.50	52.30
Payable Days	118.50	137.50	135.20	106.10	138.20	132.90	128.40	147.60	139.60	138.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

RPG Life Sciences Ltd FAQs

The current trading price of RPG Life Sciences on 03-Jul-2026 16:59 is ₹2,416.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Jul-2026 the market cap of RPG Life Sciences stood at ₹3,996.9 Cr

The latest P/E ratio of RPG Life Sciences as of 02-Jul-2026 is 34.70.

The latest P/B ratio of RPG Life Sciences as of 02-Jul-2026 is 6.60.

The 52-week high of RPG Life Sciences is ₹2,715.9 and the 52-week low is ₹1,731.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of RPG Life Sciences is ₹708 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that RPG Life Sciences Ltd is a good quality company.

The key valuation ratios of RPG Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of RPG Life Sciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About RPG Life Sciences Ltd

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The companyâ€™s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.

The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.

RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.

Major Activities of the Company:

Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
Pharmaceutical formulations & domestic marketing [SBU â€“ II] and Fermentation & biotechnology [SBU â€“ III].

Companyâ€™s Patnership:

It is represented in over thirty countries through strategic partnerships and joint ventures.

Dossiers/DMF Europe, Canada
Artificial Sweetner-UK
NSAID-Europe
Formulations - Asia, Canada, Europe.

Achievements:

8 processes patented granted,both in India and overseas
First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
One of the two manufacturers of Vitamin B12 in India
R&D approved by Department of Science & Technology, Government of India.
Only manufacturer of Spironolactone, by the fermentation route, in India.
Marketing APIs and formulations catering to all key therapeutic areas across the world.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

RPG Life Sciences Ltd (RPGLIFE)

RPG Life Sciences Ltd (RPGLIFE)

RPG Life Sciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of RPG Life Sciences - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

RPG Life Sciences Ltd FAQs

What is the share price of RPG Life Sciences?

What is the market cap of RPG Life Sciences?

What is the P/E ratio of RPG Life Sciences?

What is the P/B ratio of RPG Life Sciences?

What is the 52-week high and low of RPG Life Sciences?

What is the TTM revenue of RPG Life Sciences?

Is RPG Life Sciences Ltd a good quality company?

Is RPG Life Sciences Ltd undervalued or overvalued?

Is RPG Life Sciences Ltd a good buy now?

About RPG Life Sciences Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.